Previous studies have shown that KMO is a potential therapeutic target for several neurological diseases, such as Alzheimer's disease (AD) and Huntington's disease (HD) 47, 48. The gene discussed is KMO; the disease is early-onset autosomal dominant Alzheimer disease.